Free Trial
NYSE:CANF

Can-Fite BioPharma (CANF) Stock Price, News & Analysis

Can-Fite BioPharma logo
$1.05 +0.01 (+0.48%)
Closing price 05/16/2025 03:59 PM Eastern
Extended Trading
$1.06 +0.01 (+1.05%)
As of 05/16/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Can-Fite BioPharma Stock (NYSE:CANF)

Key Stats

Today's Range
$1.03
$1.08
50-Day Range
$1.04
$2.02
52-Week Range
$0.98
$4.69
Volume
58,177 shs
Average Volume
238,806 shs
Market Capitalization
$3.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Buy

Company Overview

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CANF Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Can-Fite Reports 2024 Financial Results and Clinical Update
See More Headlines

CANF Stock Analysis - Frequently Asked Questions

Can-Fite BioPharma's stock was trading at $1.6250 at the beginning of the year. Since then, CANF stock has decreased by 35.4% and is now trading at $1.05.
View the best growth stocks for 2025 here
.

Can-Fite BioPharma Ltd. (NYSE:CANF) announced its quarterly earnings results on Tuesday, November, 30th. The company reported ($1.90) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $1.00. The business had revenue of $0.25 million for the quarter.

Can-Fite BioPharma's stock reverse split on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Top institutional investors of Can-Fite BioPharma include Rhumbline Advisers (1.08%).

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE).

Company Calendar

Last Earnings
11/30/2021
Today
5/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:CANF
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$18.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+1,233.3%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$674,000.00
Price / Cash Flow
N/A
Book Value
$1.76 per share
Price / Book
0.60

Miscellaneous

Free Float
N/A
Market Cap
$3.72 million
Optionable
Not Optionable
Beta
1.18
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NYSE:CANF) was last updated on 5/17/2025 by MarketBeat.com Staff
From Our Partners